Presentations of Multiple Studies on Rylaze and Vyxeos at ASH 2021

As part of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Jazz Pharmaceuticals participated in 16 new studies that will be shared at the meeting. In a press release, they highlighted particularly exciting studies related to their medications, such as Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) and Vyxeos® (daunorubicin and cytarabine), being used in treatments for patients with blood cancers.

The presentation about Rylaze is the first data being shared from a phase 2/3 study of the drug in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) (Abstract 2307). Rylaze is designed to treat patients after they develop a hypersensitivity or an allergy to a long-acting E. coli–derived asparaginase. The results being shared in this poster presentation indicate positive benefits for patients with ALL/LBL when using a Rylaze regimen.

Jazz also has 10 abstracts related to Vyxeos at ASH 2021. Of note, the company is part of an oral presentation taking place about an analysis of the real-world experience of clinicians and patients using Vyxeos as first-line treatment in patients with acute myeloid leukemia (AML) (Abstract 33). Additionally, there will be data shared about other real-world analytical studies focused on the treatment patterns of patients with therapy-related AML or AML-MRC (Abstract 1248) and treatment outcomes for patients with AML when using Vyxeos (Abstract 2310).

Dr. Robert Iannone, executive vice president, research and development, and chief medical officer of the company, reiterated Jazz Pharmaceuticals commitment to collaboration and making an impact for people with hematological disorders, as well as emphasizing how the data being presented at ASH 2021 related to the company’s medications illustrates that commitment [1].

Source:

[1] Jazz Pharmaceuticals. (2021, November 4). Jazz Pharmaceuticals to present data showcasing clinical advances across Hematology/Oncology at ASH 2021 annual meeting [Press release]. https://www.obroncology.com/news/jazz-pharmaceuticals-to-present-data-showcasing-clinical-advances-across

Most Recent

Cardiovascular Disease

Cardiovascular Risk Management

Noninvasive Imaging Aids Selection of Stenosis Patients Needing Revascularization Procedure

CT fractional flow reserve analysis safely cuts rates of invasive procedures without compromising safety Computed tomography fractional flow reserve (CT-FFR) improves assessment of vessel blockages and reduces the number of stenosis patients referred for invasive revascularization procedures, according to a study published online April 4 in Radiology: Cardiothoracic Imaging. Mangun K. Randhawa, M.D., from Massachusetts General...

Oncology

Thyroid Cancer

GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer

No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online April 10 in The BMJ. Björn Pasternak, M.D., Ph.D., from...

Breast Cancer

OBGYN & Women's Health

Oncology

Mortality Up for Breast Cancer Diagnosed Five to <10 Years After Childbirth

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...